Literature DB >> 9013349

Nephrotic syndrome from 5-ASA for ulcerative colitis? Complicated by carcinoma of the colon and sclerosing cholangitis.

G Fornaciari1, S Maccari, P P Borgatti, R Rustichelli, N Amelio, I Lattuada, A C Plancher.   

Abstract

A patient with nephrotic syndrome had been treated with mesalazine for ulcerative colitis, and also had a carcinoma of the colon and sclerosing cholangitis. This seemingly unrelated series of complications gives us the opportunity to review the problem of nephropathy in ulcerative colitis.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9013349     DOI: 10.1097/00004836-199701000-00008

Source DB:  PubMed          Journal:  J Clin Gastroenterol        ISSN: 0192-0790            Impact factor:   3.062


  4 in total

1.  Acute tubular injury associated with mesalazine therapy in an adolescent girl with inflammatory bowel disease.

Authors:  Nuray Uslu; Hulya Demir; Inci Nur Saltik-Temizel; Rezan Topaloğlu; Figen Gürakan; Aysel Yüce
Journal:  Dig Dis Sci       Date:  2007-04-03       Impact factor: 3.199

2.  Inflammatory Bowel Diseases Are Associated With an Increased Risk for Chronic Kidney Disease, Which Decreases With Age.

Authors:  Ravy K Vajravelu; Lawrence Copelovitch; Mark T Osterman; Frank I Scott; Ronac Mamtani; James D Lewis; Michelle R Denburg
Journal:  Clin Gastroenterol Hepatol       Date:  2019-11-01       Impact factor: 11.382

3.  No dose-dependent tubulotoxicity of 5-aminosalicylic acid: a prospective study in patients with inflammatory bowel diseases.

Authors:  Carsten Dehmer; Roland Greinwald; Juergen Löffler; Wolfgang Grotz; Lothar Wolf; Hans-Burkhardt Hagmann; Werner Schneider; Wolfgang Kreisel
Journal:  Int J Colorectal Dis       Date:  2003-02-08       Impact factor: 2.571

4.  Nephrotic syndrome after treatment of Crohn's disease with mesalamine: Case report and literature review.

Authors:  Belal M Firwana; Rim Hasan; Walid Chalhoub; Mazen Ferwana; Jin-Yong Kang; Joshua Aron; Joseph Lieber
Journal:  Avicenna J Med       Date:  2012-01
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.